Nurix Therapeutics, Inc. 4

Chief Scientific Officer Gwenn Hansen exercised 4,356 Nurix Therapeutics (NRIX) options at $1.86 and sold 4,356 common shares at $25.00 on 2026-08-05 under a Rule 10b5-1 plan.

On August 5, 2026, Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen exercised an employee stock option for 4,356 shares of common stock at $1.86 per share and immediately sold the same 4,356 shares at $25.00 per share under a pre-arranged Rule 10b5-1 trading plan. The option exercise (coded “M”) reflects a cost basis of approximately $8,101 before tax, and the market sale generated gross proceeds of about $108,900, implying a spread of roughly $100,800. After these transactions, Hansen’s direct common stock holdings decreased from 121,583 shares pre-sale to 117,227 shares, with an estimated post-transaction holding value of about $2.93 million based on the $25 sale price. The option exercised was part of a grant that vested monthly from June 10, 2019, through May 10, 2023, indicating this was a routine, fully vested option exercise and sale rather than a new equity award or open-market purchase.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817160-26-000017

Alert Tier

5